2012
DOI: 10.1016/b978-0-12-397220-0.00005-2
|View full text |Cite
|
Sign up to set email alerts
|

Gatifloxacin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(5 citation statements)
references
References 69 publications
0
5
0
Order By: Relevance
“…The NMR assignment of gatifloxacin in D 2 O was carried out as reported in the literature [ 70 ]. The proton signal of –CH- linked to the secondary amine of gatifloxacine was shifted from 4.12 ppm to 4.07 ppm after the addition of Cross-PEI-800 ( Figure 6 a,b, full spectra shown in Figures S13–S15 in the Supplementary Materials ).…”
Section: Resultsmentioning
confidence: 99%
“…The NMR assignment of gatifloxacin in D 2 O was carried out as reported in the literature [ 70 ]. The proton signal of –CH- linked to the secondary amine of gatifloxacine was shifted from 4.12 ppm to 4.07 ppm after the addition of Cross-PEI-800 ( Figure 6 a,b, full spectra shown in Figures S13–S15 in the Supplementary Materials ).…”
Section: Resultsmentioning
confidence: 99%
“…Gatifloxacin was shown to be highly active against both penicillin-susceptible and penicillin-resistant strains of S. pneumoniae , the main pathogen behind the bacterial pneumonia infection. 278 This 8-methylfluoroquinolone derivative has been used to treat lung, sinus, skin, and urinary-tract infections but has also been shown to produce dangerous changes in blood-sugar levels. Although the complete mechanism leading to hypoglycemia is not yet fully understood, experiments have shown that it can stimulate insulin release and block the ATP-sensitive potassium channels of pancreatic cells, which can both lead to hypoglycemia.…”
Section: Fluorine-containing Pharmaceuticals Withdrawn From the Marketmentioning
confidence: 99%
“…Approved for sale and commercialized with the brand name Tequin by Bristol-Myers Squibb in 1999, gatifloxacin 158 (Figure ) is a member of the fourth and latest generation of the fluoroquinolone family of antibiotics. Gatifloxacin was shown to be highly active against both penicillin-susceptible and penicillin-resistant strains of S. pneumoniae , the main pathogen behind the bacterial pneumonia infection . This 8-methylfluoroquinolone derivative has been used to treat lung, sinus, skin, and urinary-tract infections but has also been shown to produce dangerous changes in blood-sugar levels.…”
Section: Fluorine-containing Pharmaceuticals Withdrawn From the Marketmentioning
confidence: 99%
“…Fluoroquinolones are considered one of the most effective drug classes for the treatment of ocular bacterial infections, mainly due to their broad spectrum activity and high potency [ 5 ]. Moxifloxacin (MOX) and gatifloxacin (GTX) solutions were introduced in 2003 as two new fourth generation fluoroquinolones for the treatment of BC [ 6 ].…”
Section: Introductionmentioning
confidence: 99%